Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page

First-in-man implantation of left subclavian artery branched TEVAR device conducted in the USA

Friday, 19 Apr 2013 12:15
Eric Roselli
Eric Roselli

The first-in-man experience with a new branched thoracic aortic arch stent graft was performed on 11 April 2013 at the Carolinas HealthCare System’s Sanger Heart & Vascular Institute, Charlotte, USA. The procedure with the Medtronic Valiant Mona device, designed with a branch to preserve the left subclavian artery (LSA), was led by Frank Arko.

Two days before the first procedure, Eric Roselli, from the Cleveland Clinic, spoke about the device at the Charing Cross International Symposium (CX35, 6–9 April 2013, London, UK) in the talk “Endovascular management of the left subclavian artery during TEVAR: Valiant LSA branched device”.

“From 17% to 43% of patients undergoing TEVAR have planned coverage of the left subclavian artery,” he said. “Coverage of the left subclavian artery without revascularisation is the single most important predictor of stroke after TEVAR. It can also cause spinal cord ischaemia (4%), arm ischaemia (6%) and death (6%).”

Roselli explained that the Valiant Mosa LSA Stent Graft System has two components: a main stent graft and a branched stent graft. He added, “The Captivia Delivery System has been modified to accommodate two wires; the primary wire delivers the main stent graft and the secondary wire delivers the left subclavian artery branch graft. The secondary wire is inserted into the lumen at the base of the delivery system, extends through the stent graft and exits out the left subclavian artery branch cuff and through the tapered tip. The delivery system includes tip capture consistent with the Captivia design.”

The left subclavian artery branch graft is constructed of a nitinol helical wire formed stent and polyester fabric. It has a distal flare, which mates with the branch cuff to provide good sealing and fixation. The diameters of 10, 12 and 14mm are appropriate for the left subclavian artery diameters ranging from 8mm to 13mm. Roselli said that the branch graft is offered in one length, which accommodates most anatomies. The branch stent graft is delivered with the femoral approach using a modified (longer length) 15F Endurant limb delivery system.

Roselli told CX35 delegates that the Medtronic Early Feasibility Study Valiant Mona LSA Thoracic Stent Graft System will enrol seven to nine patients at two centres (Carolinas HealthCare System’s Sanger Heart & Vascular Institute and Cleveland Clinic). The objectives are to validate the procedure in humans, assess the safety and performance with the device acutely and at 30 days and collect imaging data to augment the current understanding of the technique.

The feasibility study with the device is one of nine chosen by the FDA for a pilot programme to encourage and facilitate early feasibility studies of innovative medical devices for first-in-human trials in the United States.

In the conclusion of his presentation at CX35, Roselli stated that better disease-specific devices are needed. He went on to say that left subclavian artery preservation during TEVAR is important and that the new FDA innovation pathway may allow rapid development and approval process of a left subclavian artery branched graft device.

Valiant Mona LSA
Valiant Mona LSA

Add New Comment

Most popular

Incraft low-profile endograft launched in Europe and Canada
Wednesday, 10 Sep 2014
Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from ... Incraft low-profile endograft launched in Europe and Canada

First patient enrolled in US study of Novate’s Sentry IVC filter
Monday, 22 Sep 2014
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE ... First patient enrolled in US study of Novate’s Sentry IVC filter

First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA


Not all drug-eluting balloons are equal
Wednesday, 15 Oct 2014
Thomas Zeller, Bad Krozingen, Germany, analyses the results of two recent randomised controlled trials comparing drug-eluting balloons to angioplasty alone in femoropopliteal lesions. Not all drug-eluting balloons are equal

Renal stenting may benefit patients excluded from randomised trials, says expert consensus
Wednesday, 15 Oct 2014
Sahil A Parikh, Case Western Reserve University School of Medicine, Cleveland, USA, speaks to Vascular News about the Society for Cardiovascular Angiography and Interventions expert consensus on ... Renal stenting may benefit patients excluded from randomised trials, says expert consensus


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions